The launch of SpringWorks Therapeutics' initial public offering Friday raised $162 million after the company sold 9 million shares at $18 per share, with the funds to be used to support research for products in its development pipeline. SpringWorks' most advanced candidate is nirogacestat, a cancer treatment for desmoid tumors that is being evaluated in a late-stage trial, with preliminary data from this trial expected to become available in 2021.
SpringWorks gains $162M from IPO launch
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.